Contrast-enhanced ultrasound for examining tumor biology.
This paper reviews the potential of ultrasound for assessing the viability and biological behavior of tumors. Unlike color Doppler sonography, modern techniques for contrast-enhanced ultrasound permit the measurement of tissue perfusion irrespective of vessel size or flow velocity. Perfusion can also be assessed quantitatively, using replenishment kinetics or derivates thereof. The perfusion of tumors is a surrogate parameter of their viability and may mirror their response to therapy. Furthermore, the degree of vascularity in a tumor may express its aggressiveness and help to predict its response to treatment. In animal models, a decrease in blood flow has been shown to precede a shrinkage of tumors treated with anti-angiogenic compounds. In liver metastases, arterial and portal blood supply can be assessed separately, and a response to stereotactic radiotherapy was found to go along with a decrease in arterial perfusion. Moreover, a relatively high arterial perfusion of liver metastases may predict a response to chemotherapy. Contrast-enhanced ultrasound may be a potent tool for assessing the effects of anti-angiogenic treatment in patients.
Delorme
Stefan
S
German Cancer Research Center (dkfz), Department of Radiology (E010), Heidelberg, Germany.
Krix
Martin
M
D000388:Air; D000818:Animals; D003287:Contrast Media; D005740:Gases; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging*; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000000981:diagnostic imaging; D010743:Phospholipids; D011134:Polysaccharides; D013459:Sulfur Hexafluoride; D018615:Ultrasonography, Doppler, Color
D003287:Contrast Media; D005740:Gases; D010743:Phospholipids; D011134:Polysaccharides; C420843:contrast agent BR1; C059891:SHU 508; D013459:Sulfur Hexafluoride